Skip to content

Epstein-Barr Virus VCA IgM Control Serum BC1361M

$94.00

Summary

  • Virion/Serion Diagnostic Kit Control for research use (RUO)
  • Epstein-Barr Virus VCA IgM Control Serum
  • Applications: ELISA
  • IgM control serum
  • Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
  • 3 mL

Order now and receive on May 30, 2024

Calculate shipping price

Please fill in the fields below with the shipping destination details in order to calculate the shipping cost.

SKU: BC1361M Category: Tag:
Weight1 lbs
Dimensions9 × 5 × 2 in
target

Epstein-Barr Virus VCA reactive IgM

species reactivity

Epstein-Barr Virus (EBV)

applications

ELISA

assay type

Indirect & quantitative

available size

3 mL

kit
Research area
Infectious Disease
Storage
Store at 2-8°C.
Associated products
Epstein-Barr Virus (EBV) Capsid Antigen P18, alternative buffer Control Antigen (BA1361R01)
Epstein Barr Virus (EBV) Capsid Antigen (BA1361VSR21)
Epstein Barr Virus (EBV) Capsid Antigen (BA1361VSR22)
Epstein Barr Virus (EBV) Nuclear Antigen (BA1362VS)
Epstein Barr Virus (EBV) Early Antigen (BA1363P54VS)
Epstein Barr Virus (EBV) Early Antigen (BA1363VSR6)
Epstein-Barr Virus VCA IgG Control Serum (BC1361G)
Epstein-Barr Virus VCA IgM Control Serum (BC1361M)
Epstein-Barr Virus EBNA-1 IgG Control Serum (BC1362G)
Epstein-Barr Virus EA IgG Control Serum (BC1363G)
Epstein-Barr Virus/VCA IgM ELISA Kit (ESR1361M)
Epstein-Barr Virus EA IgG ELISA Kit (ESR1363G)
target relevance
Organism
Epstein-Barr Virus
Structure and strains
The Epstein Barr virus (EBV), formally called Human gammaherpesvirus 4, is one of the nine known human herpesvirus types in the herpes family, and is one of the most common viruses in humans. EBV is a double-stranded DNA virus. Epstein-Barr virus (EBV) is the first identified oncogenic virus, which establishes permanent infection in humans. EBV causes infectious mononucleosis and is also tightly linked to many malignant diseases. Various vaccine formulations underwent testing in different animals or in humans. However, none of them was able to prevent EBV infection and no vaccine has been approved to date.

The virus causes infectious mononucleosis ("mono" or "glandular fever"). It is also associated with various non-malignant, premalignant, and malignant Epstein Barr virus-associated lymphoproliferative diseases such as Burkitt lymphoma, hemophagocytic lymphohistiocytosis, and Hodgkin's lymphoma; non-lymphoid malignancies such as gastric cancer and nasopharyngeal carcinoma; and conditions associated with human immunodeficiency virus such as hairy leukoplakia and central nervous system lymphomas. The virus is also associated with the childhood disorders of Alice in Wonderland syndrome and acute cerebellar ataxia and, by some evidence, higher risks of developing certain autoimmune diseases, especially dermatomyositis, systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's syndrome. About 200,000 cancer cases globally per year are thought to be attributable to EBV. In 2022, a large study (population of 10 million over 20 years) suggested EBV as the leading cause of multiple sclerosis, with a recent EBV infection causing a 32-fold increase in the risk of developing multiple sclerosis.
Disease
The Epstein-Barr Virus is a worldwide distributed human pathogenic DNA virus of the family Herpesviridae. Seroprevalence in adults is high (90-95%). In adolescents and younger adults, infection with EBV frequently leads to the clinical manifestation of infectious mononucleosis.

In primary EBV infections, cells of the salivary gland are infected first. This disease stage is accompanied by mild flu-like symptoms. As soon as the virus infects B cells in the adjacent lymphoid tissue and spreads throughout the body, the clinical picture of infectious mononucleosis or glandular fever occurs. This disease is usually characterized by high fever, splenomegalia, lymphadenitis, and thrombocytopenia. Furthermore, EBV infections are associated with nasopharyngeal carcinoma and Burkitt's lymphoma in some regions.
Detection and diagnosis
IgG antibodies directed against early antigen (EA) and/or IgM antibodies against virus capsid antigens (VCA) in combination with negative EBNA1 IgG activity serve as evidence of acute primary infections. High IgG antibody activities against EBNA1 exclude acute primary infections. IgG antibodies directed against VCA can usually be detected life-long and serve as confirmation of contact with the pathogen. In reactivations, high IgG antibody activities directed against VCA and EA can frequently be found.

Data

Publications

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.

pmidtitleauthorscitation

Protocols

relevant to this product
BC1361M protocol

Documents

#
No results found

Reviews

There are no reviews yet.

Be the first to review “Epstein-Barr Virus VCA IgM Control Serum BC1361M”